Not conducted (no test models or relevant species); integration site analysis showed polyclonal products, no selective insertion
“Conventional genotoxicity studies were not conducted with afamitresgene autoleucel, due to the lack of appropriate test models and pharmacologically relevant species.”
✓ VerifiedFDA multi-discipline review, p. 40Source ↗
Carcinogenicity
Not conducted (no relevant animal models for human TCR-engineered T cells)
“Afamitresgene autoleucel is a human TCR engineered T-cell product, therefore conventional carcinogenicity studies were not performed due to the lack of relevant animal models.”
✓ VerifiedFDA multi-discipline review, p. 40Source ↗
Reproductive & developmental
Not conducted; theoretical testis/placenta risk (MAGE-A4 expression) judged mitigated by immune privilege, labeling, pharmacovigilance
“MAGE-A4 is known to be expressed in testes and placenta, and so there is a theoretical risk of embryotoxicity or toxicity to the testes.”
✓ VerifiedFDA multi-discipline review, p. 40Source ↗
Safety pharmacology
Not conducted; no relevant animal models
“No safety pharmacology studies were conducted, as there are no relevant animal models for the nonclinical safety assessment of afamitresgene autoleucel.”
✓ VerifiedFDA multi-discipline review, p. 39Source ↗